Evidence map›Paper›PMID 37198323›Full record

ArticleLeukemia2023

UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease.

Ola Rizq, Naoya Mimura, Motohiko Oshima, Shuji Momose, Naoya Takayama, Naoki Itokawa, Shuhei Koide, Asuka Shibamiya, Yurie Miyamoto-Nagai, Mohamed Rizk and 19 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 8 institutions in 3 countries.

Ola Rizq *Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Naoya Mimura *Department of Hematology, Chiba University Hospital, Chiba, Japan. naoyamimura@chiba-u.jp.
Motohiko OshimaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.ORCID 0000-0003-3986-1409
Naoya TakayamaDepartment of Regenerative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Naoki ItokawaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shuhei KoideDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Asuka ShibamiyaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Yurie Miyamoto-NagaiDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Mohamed RizkDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yaeko Nakajima-TakagiDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kazumasa AoyamaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Changshan WangDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Atsunori SarayaDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ryoji ItoCentral Institute for Experimental Animals, Kanagawa, Japan.
Masanori SeimiyaDepartment of Medical Technology and Sciences, School of Health Sciences at Narita, International University of Health and Welfare, Narita, Japan.
Mariko WatanabeDepartment of Clinical Laboratory, Chiba University Hospital, Chiba, Japan.
Satoshi YamasakiLaboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tatsuhiro ShibataLaboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kiyoshi YamaguchiDivision of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-2113-4369
Yoichi FurukawaDivision of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tetsuhiro ChibaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.ORCID 0000-0002-7254-1928
Chiaki NakasekoDepartment of Hematology, International University of Health and Welfare, Narita, Japan.
Jun-Ichi TamaruDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Yu-Tzu TaiJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6199-3569
Kenneth C AndersonJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6418-0886
Hiroaki HondaField of Human Disease Models, Major in Advanced Life Sciences and Medicine, Institute of Laboratory Animals, Tokyo Women's Medical University, Tokyo, Japan.
Atsushi IwamaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. 03aiwama@ims.u-tokyo.ac.jp.ORCID 0000-0001-9410-8992
Chiba University · JPThe University of Tokyo · JPChiba University Hospital · JPHarvard University · USInternational University of Health and Welfare · JPSocial Insurance Saitama Chuo Hospital · JPCentral Institute for Experimental Animals · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

UTX/KDM6A, a histone H3K27 demethylase and a key component of the COMPASS complex, is frequently lost or mutated in cancer; however, its tumor suppressor function remains largely uncharacterized in multiple myeloma (MM). Here, we show that the conditional deletion of the X-linked Utx in germinal center (GC) derived cells collaborates with the activating Braf

Indexed as

Multiple MyelomaAnimalsB-LymphocytesGenes, Tumor SuppressorGerminal CenterHistone DemethylasesMiceProto-Oncogene Proteins B-rafHistone DemethylasesProto-Oncogene Proteins B-rafUtx protein, mouse

Identifiers

PMID37198323
PMCPMC10457198
OpenAlexW4377011099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.